Neurotrophins reportedly improve hearing outcomes when used in combination with cochlear implants, as they promote the survival of spiral ganglion neurons (SGNs) and stimulate SGN neurite outgrowth in animal models of sensorineural hearing loss. However, their applicability to human patients remains unknown. This review examines the clinical applicability of neurotrophins based on advances in drug delivery techniques to the inner ear and discusses their potential for future application in human patients.
Seung Cheol Ahn (Mon,) studied this question.